Detalhe da pesquisa
1.
Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases.
Hematol Oncol
; 41(1): 50-60, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251440
2.
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
Ann Hematol
; 100(5): 1213-1219, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33677654
3.
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols.
Acta Oncol
; 60(11): 1520-1526, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34461798
4.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34499575
5.
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Ann Hematol
; 99(10): 2405-2416, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32813071
6.
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients.
Ann Hematol
; 99(12): 2773-2777, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32462330
7.
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
Ann Hematol
; 98(8): 1919-1925, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168652
8.
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Ann Hematol
; 98(8): 1891-1904, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31079264
9.
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
Am J Hematol
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38769689
10.
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
Ann Hematol
; 97(10): 1803-1808, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29806063
11.
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?
Eur J Haematol
; 2018 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29896890
12.
Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia.
Hematol Oncol
; 35(4): 804-809, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27400753
13.
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Ann Hematol
; 96(3): 387-391, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27889820
14.
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.
Am J Hematol
; 92(1): 37-41, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27701770
15.
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab.
Ann Hematol
; 100(8): 2117-2119, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856142
16.
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
Ann Hematol
; 94(2): 195-200, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25186786
17.
Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome.
Hematol Oncol
; 37(5): 652-654, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321792
18.
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells.
Ann Hematol
; 93(11): 1819-23, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24912771
19.
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.
Br J Haematol
; 182(3): 427-429, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28677850
20.
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Br J Haematol
; 181(2): 275-278, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211562